GPE GLOBALPHARMA OÜ
Date of report 25.11.2024
GPE GLOBALPHARMA OÜ
Former names
- KemLab OÜ
start | end |
---|---|
15.10.2012 | - |
keywords
- pakendamine
GPE GLOBALPHARMA OÜ
Scores and ratings
Reputation score
Credit Score
Open the reports you want to print
Employees and salaries
GPE GLOBALPHARMA OÜ
Employee taxes and performance analysisQuarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
---|---|---|---|---|
2024 III | ...... | ...... | ...... | ...... |
2024 II | ...... | ...... | ...... | ...... |
2024 I | ...... | ...... | ...... | ...... |
2023 IV | ...... | ...... | ...... | ...... |
2023 III | ...... | ...... | ...... | ...... |
2023 II | ...... | ...... | ...... | ...... |
2023 I | ...... | ...... | ...... | ...... |
2022 IV | ...... | ...... | ...... | ...... |
2022 III | ...... | ...... | ...... | ...... |
2022 II | ...... | ...... | ...... | ...... |
2022 I | ...... | ...... | ...... | ...... |
2021 IV | ...... | ...... | ...... | ...... |
2021 III | ...... | ...... | ...... | ...... |
2021 II | ...... | ...... | ...... | ...... |
2021 I | ...... | ...... | ...... | ...... |
2020 IV | ...... | ...... | ...... | ...... |
2020 III | ...... | ...... | ...... | ...... |
2020 II | ...... | ...... | ...... | ...... |
2020 I | ...... | ...... | ...... | ...... |
2019 IV | ...... | ...... | ...... | ...... |
2019 III | ...... | ...... | ...... | ...... |
2019 II | ...... | ...... | ...... | ...... |
2019 I | ...... | ...... | ...... | ...... |
2018 IV | ...... | ...... | ...... | ...... |
2018 III | ...... | ...... | ...... | ...... |
2018 II | ...... | ...... | ...... | ...... |
2018 I | ...... | ...... | ...... | ...... |
2017 IV | ...... | ...... | ...... | ...... |
2017 III | ...... | ...... | ...... | ...... |
2017 II | ...... | ...... | ...... | ...... |
2017 I | ...... | ...... | ...... | ...... |
2016 IV | ...... | ...... | ...... | ...... |
2016 III | ...... | ...... | ...... | ...... |
2016 II | ...... | ...... | ...... | ...... |
2016 I | ...... | ...... | ...... | ...... |
2015 IV | ...... | ...... | ...... | ...... |
2015 III | ...... | ...... | ...... | ...... |
2015 II | ...... | ...... | ...... | ...... |
2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
GPE GLOBALPHARMA OÜ
DecidersFormer deciders
......
Credit Score: Trustworthy
Reputation scores: 6470
Date of birth: ......
Active relations 13
31 followers
......
Credit Score: Trustworthy
Reputation scores: 590
Date of birth: ......
Active relations 1
0 followers
......
Credit Score: Trustworthy
Reputation scores: 2030
Date of birth: ......
Active relations 4
2 followers
GPE GLOBALPHARMA OÜ
Former deciders......
Credit Score: Trustworthy
Reputation scores: 13620
Date of birth: ......
Active relations 6
12 followers
GPE GLOBALPHARMA OÜ
History of right of representationGPE GLOBALPHARMA OÜ
OwnersFormer owners
GPE GLOBALPHARMA OÜ
Other related partiesFormer other persons
Name | Credit Score | Part | Beginning |
---|---|---|---|
...... | ...... |
Beneficiaries
Volumes and values of beneficiaries' assets
Finances and assets
GPE GLOBALPHARMA OÜ
GoodwillGPE GLOBALPHARMA OÜ
Paid taxes and estimated average salariesGPE GLOBALPHARMA OÜ
Quarterly indicatorsQuarter | Turnover | Taxed turnover | Labor productivity | Labor productivity | Employees | National taxes | Labor taxes |
---|---|---|---|---|---|---|---|
2024 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
GPE GLOBALPHARMA OÜ
Sales revenue by business areaGPE GLOBALPHARMA OÜ
Sales revenue by countryGPE GLOBALPHARMA OÜ
Financial indicators and prognosisGPE GLOBALPHARMA OÜ
Financial raiting: "VERY GOOD" (2024 prognosis)GPE GLOBALPHARMA OÜ
Annual reportsYear | Period | Submitted | Report PDF |
---|---|---|---|
2023 | 01.01.2023–31.12.2023 | 29.06.2024 | ...... |
2022 | 01.01.2022–31.12.2022 | 27.02.2023 | ...... |
2021 | 01.01.2021–31.12.2021 | 06.05.2022 | ...... |
2020 | 01.01.2020–31.12.2020 | 04.05.2021 | ...... |
2019 | 01.01.2019–31.12.2019 | 25.06.2020 | ...... |
2018 | 01.01.2018–31.12.2018 | 09.12.2019 | ...... |
2017 | 01.01.2017–31.12.2017 | 28.06.2018 | ...... |
2016 | 01.01.2016–31.12.2016 | 07.07.2017 | ...... |
2015 | 01.01.2015–31.12.2015 | 04.07.2016 | ...... |
2014 | 01.01.2014–31.12.2014 | 29.06.2015 | ...... |
2013 | 01.01.2013–31.12.2013 | 26.06.2014 | ...... |
2012 | 01.01.2012–31.12.2012 | 30.06.2013 | ...... |
Liabilities and debts
GPE GLOBALPHARMA OÜ
Credit score history and prognosis... €
......
Business risk classes:
Trustworthy NeutralGPE GLOBALPHARMA OÜ
Reports and assets-liabilities overview 25.11.2024GPE GLOBALPHARMA OÜ
Claims historyTotal debt claims: ...... €
...... | ...... |
GPE GLOBALPHARMA OÜ
Income (turnover) and expenditure (taxes paid)Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
---|---|---|---|---|---|
2024 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 I | * ...... € | ...... € | ...... € | ...... € | ...... |
GPE GLOBALPHARMA OÜ
Bailiff's enforcement proceedings as of 25.11.2024Bailiff's enforcement proceedings MISSING
GPE GLOBALPHARMA OÜ
Regulations of the Payment Order Department as of 25.11.2024Regulations of the Payment Order Department MISSING
GPE GLOBALPHARMA OÜ
Court orders in the register as of 25.11.2024Korraldav määrus
Regulation number: Ä 20060646 / M3
Regulation status has entered into force: 28.10.2020
Date of enforcement of order or additional period: 28.10.2020
Määruse olek: Jõustunud
Hoiatusmäärus sundlõpetamiseks: ebapiisav netovara
Regulation number: Ä 20060646 / M2
Regulation status has entered into force: 25.02.2020
Date of enforcement of order or additional period: 25.02.2020
Määruse olek: Jõustunud
GPE GLOBALPHARMA OÜ
Decisions of the Consumer Disputes Committee as of 25.11.2024Consumer disputes MISSING
GPE GLOBALPHARMA OÜ
Court hearings as of 25.11.2024Court hearings MISSING
GPE GLOBALPHARMA OÜ
Rulings as of 25.11.2024Court settlemets MISSING
GPE GLOBALPHARMA OÜ
Notices and announcements as of 25.11.2024Announcements MISSING
Marketing
Business network
GPE GLOBALPHARMA OÜ
Business networkSign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
GPE GLOBALPHARMA OÜ
Networks - BeneficiariesSign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events were found
Failed to load monitoring events